Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.
The paper follows closely on research published by the same lab in late February that demonstrated how the drug worked against the Middle East Respiratory Syndrome (MERS) virus, a related coronavirus.
“We were optimistic that we would see the same results against the SARS-CoV-2 virus,” said Matthias Götte, chair of medical microbiology and immunology at U of A.
“We obtained almost identical results as we reported previously with MERS, so we see that remdesivir is a very potent inhibitor for coronavirus polymerases.”
Götte’s new paper demonstrates how remdesivir, developed in 2014 to fight the Ebola epidemic, works in detail. He likens the polymerase to the engine of the virus, responsible for synthesizing the virus’ genome.
“If you target the polymerase, the virus cannot spread, so it’s a very logical target for treatment,” Götte said.
The lab’s work shows how remdesivir tricks the virus by mimicking its building blocks.
“These coronavirus polymerases are sloppy and they get fooled, so the inhibitor gets incorporated many times and the virus can no longer replicate,” Götte explained.
He said the evidence from his group, along with previously published studies in animal and cell culture models, means that remdesivir can be classified as a “direct-acting antiviral” against SARS-CoV-2, a term first used to describe newer classes of antivirals that interfere with specific steps of the hepatitis C virus (HCV) life cycle.
He said the discovery of that direct action reinforces the promise of clinical trials for remdesivir in COVID-19 patients, which are already underway around the world.
While Götte said the evidence justifies clinical trials, he cautioned that the results obtained in the lab cannot be used to predict how the drug will work with people.
“We’ve got to be patient and wait for the results of the randomized clinical trials,” said Götte, whose research was funded by the Canadian Institutes of Health Research, Alberta’s Major Innovation Fund and Gilead Sciences, which manufactures remdesivir.
Collaboration a cause for hope
The Götte lab previously worked on human immunodeficiency virus (HIV) and HCV, but a couple of years ago switched to focus on viruses with the highest epidemic potential. The World Health Organization (WHO) issued its list of the top pathogens likely to cause severe outbreaks, including Ebola, Lassa and coronaviruses, in 2015.
“In that sense we were prepared because my lab specializes in viral polymerases,” said Götte, adding that his next step will be to use his lab’s tools to evaluate other promising antivirals.
He is optimistic that the unprecedented amount of research going on worldwide and the high level of co-operation between researchers will lead to the discovery of one or more effective treatments for COVID-19.
“We are desperate, but we still have to keep the bar high for anything that we put into clinical trials,” he said.
Remdesivir is one of several drugs being fast-tracked into trials by the World Health Organization, comparing potential treatments in hospitalized COVID-19 patients in a dozen countries, including Canada. Götte said we can expect results from important clinical trials as early as April or May.
Götte said it is disappointing that antivirals discovered at the time of the severe acute respiratory syndrome (SARS) outbreak of 2003—which might have been effective against COVID-19 too—were never translated into widely available treatments, largely because of the huge cost involved in developing new drugs.
“This time around it’s obvious that we have to cross the finish line,” he said.
“Ten billion dollars, it seems a lot, a huge amount,” Götte said. “But in the context of this pandemic and the costs associated with this pandemic, it’s nothing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- European countries face shortages of COVID-19 drug remdesiviron October 6, 2020 at 7:41 pm
European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of ...
- Trump's coronavirus treatments: Remdesivir, regeneron and more, explainedon October 6, 2020 at 3:04 pm
President Donald Trump returned to the White House on Monday after announcing Thursday he'd tested positive for coronavirus and spending three nights at Walter Reed National Military Medical Center.
- Britain rations remdesivir as COVID-19 hospitalisations riseon October 6, 2020 at 8:56 am
Britain has rationed its supplies of the antiviral drug remdesivir and is prioritising COVID-19 patients who need it most in the face of rising demand, Britain's health ministry said on Tuesday, with ...
- Dexamethasone, remdesivir, Regeneron: Trump's Covid treatment explainedon October 5, 2020 at 8:03 pm
The US president has been given a number of different medicines to attack coronavirus and calm the immune system. What are they, and why is he taking them?
- Dexamethasone, remdesivir and more: 5 takeaways from Dr. Sean Conley's Sunday update on Donald Trump's COVID-19 healthon October 4, 2020 at 5:19 pm
Although Trump and his doctors claim the president will be discharged from Walter Reed as early as tomorrow, some health experts are troubled.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- SARS-CoV-2 spike protein may induce analgesiaon October 6, 2020 at 11:17 pm
A recent study published in the journal Pain in October 2020 adds another piece to the puzzle, showing that the virus is capable of dulling pain pathways. This may contribute to its early and ...
- Proteolytic activation of the SARS-CoV-2 spike S1/S2 siteon October 6, 2020 at 7:15 pm
In a recent paper published on the bioRxiv preprint server, Cornell University researchers study the proteolytic activation of the SARS-CoV-2 spike sites, re-evaluating the furin cleavage.
- FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccineon October 6, 2020 at 2:48 pm
(NYSE American: OGEN) ("Oragenics" or the "Company") announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration ("FDA") that it is in broad ...
- SARS-CoV-2 may use key carbohydrate to infect cellson October 6, 2020 at 12:33 pm
A carbohydrate called heparan sulfate, which is found on cell surfaces, may play a critical role in the novel coronavirus’ ability to infect cells.
- Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)on October 6, 2020 at 6:08 am
SAN DIEGO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly ...